[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-mellitus-type-2-childhood-onset\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-mellitus-type-2-childhood-onset":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100556450","discovery-of-risk-factors-for-type-2-diabetes-in-youth-100556450",false,"NCT06525259","DISCOVERY of Risk Factors for Type 2 Diabetes in Youth","DISCOVERY","Inclusion Criteria:\n\nScreening will occur to enrich the yield of individuals who are highly predisposed to develop youth-onset T2D and include those with all of the following criteria:\n\n* Overweight or obesity with BMI ≥85th percentile\n* Age 8-13 year for girls, 9-15 year for boys (inclusion younger for girls as puberty tends to start a year earlier in girls)\n* Tanner Stage 2, 3, or 4\n* Elevated HbA1c 5.5-6.4%\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation:\n\n* Diabetes based on history, or HbA1c ≥6.5% in the medical record or at screening\n* Unable\u002Funwilling to provide consent\u002Fparticipate fully\n* Conditions predisposing to diabetes or altering the trajectory of puberty\n* Medications affecting glucose dynamics during the screening and enrollment period\n* Prior treatment with insulin\n* Use of glucagon-like peptide-1 (GLP-1) receptor agonist or any weight loss medications in the 6 weeks prior to enrollment\n* Planning treatment with glucagon-like peptide-1 (GLP-1) receptor agonist or any weight loss medications\n* Use of metformin or any glucose lowering medication for a reason other than treatment of diabetes (e.g., for PCOS) in the 6 weeks prior to enrollment\n* Planning treatment with metformin or any glucose lowering medication or planning to use such medications for a reason other than treatment of diabetes (e.g., for PCOS)\n* Known syndromic\u002Fmonogenic obesity\n* Blood disorders impacting HbA1c (e.g., anemia, hemoglobin variants)\n* Major systemic organ disease\n* History of bariatric surgery or currently planning bariatric surgery\n* Current pregnancy or currently planning pregnancy\n* Use of GnRH agonist, estrogen, or testosterone\n* Individuals who do not speak English or Spanish, given validation of the questionnaires to be utilized","ALL","8 Years","15 Years",{"count":20,"type":21},3600,"ESTIMATED","OBSERVATIONAL","The goal of the DISCOVERY study is to provide innovative critical information regarding the unique natural history of glycemic control, insulin sensitivity, and β-cell function, and their mechanistic determinates, in obese adolescents at risk for developing type 2 diabetes.",[25],"Diabetes Mellitus Type 2, Childhood-Onset","RECRUITING","2026-05-06",{"date":29,"type":30},"2026-05-07","ACTUAL",{"date":32,"type":30},"2024-10-01",{"date":34,"type":21},"2028-01-31",{"name":36,"class":37},"George Washington University","OTHER",20]